News & Blog
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
2023 – A Year in Retrospect
MEC in 4Q23: Pioneering the Future of Precision Medicine – More in 2024
Immunitas Therapeutics Appoints Annalisa D’Andrea, Ph.D., as Chief Scientific Officer
Pleno Deploys its RAPTOR Instrument Platform Available with TotalSeq™ Antibodies from BioLegend
SonoThera’s CEO Ken Greenberg interviewed by Wilson Sonsini’s Dustin Luettgen in the latest edition of the Life Sciences Report
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting
AVILAR THERAPEUTICS TO PRESENT NEW DATA FOR ATAC EXTRACELLULAR PROTEIN DEGRADERS AT TARGETED PROTEIN DEGRADATION SUMMIT